Blinatumomab, the first FDA-approved BiTE antibody, has been shown to extend the median survival to 7.7 months in patients with CD19+, Philadelphia chromosome (Ph)––negative R/R ALL [11] (Table 1). Here, CD19 is linked to acute lymphoblastic leukemia.